BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2140111)

  • 1. Treatment of bone and soft tissue infections with teicoplanin.
    Marone P; Concia E; Andreoni M; Suter F; Cruciani M
    J Antimicrob Chemother; 1990 Mar; 25(3):435-9. PubMed ID: 2140111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teicoplanin in the treatment of skin and soft tissue infections.
    Turpin PJ; Taylor GP; Logan MN; Wood MJ
    J Antimicrob Chemother; 1988 Jan; 21 Suppl A():117-22. PubMed ID: 2965123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teicoplanin in the treatment of infections by staphylococci, Clostridium difficile and other gram-positive bacteria.
    de Lalla F; Santoro D; Rinaldi E; Suter F; Cruciani M; Guaglianone MH; Rizzardini G; Pellegata G
    J Antimicrob Chemother; 1989 Jan; 23(1):131-42. PubMed ID: 2526109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evaluation of teicoplanin for therapy of severe infections caused by gram-positive bacteria.
    Glupczynski Y; Lagast H; Van der Auwera P; Thys JP; Crokaert F; Yourassowsky E; Meunier-Carpentier F; Klastersky J; Kains JP; Serruys-Schoutens E
    Antimicrob Agents Chemother; 1986 Jan; 29(1):52-7. PubMed ID: 2942100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of infections by staphylococci and other gram-positive bacteria with teicoplanin: an open study.
    Pauluzzi S; Del Favero A; Menichetti F; Baratta E; Moretti VM; Di Filippo P; Pasticci MB; Guerciolini R; Patoia L; Frongillo RF
    J Antimicrob Chemother; 1987 Sep; 20(3):431-8. PubMed ID: 2960643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicentre open clinical trial of teicoplanin in infections caused by gram-positive bacteria.
    Lewis P; Garaud JJ; Parenti F
    J Antimicrob Chemother; 1988 Jan; 21 Suppl A():61-7. PubMed ID: 2965133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teicoplanin in the treatment of bone and joint infections. Teicoplanin Bone and Joint Cooperative Study Group, USA.
    LeFrock JL; Ristuccia AM; Ristuccia PA; Quenzer RW; Haggerty PG; Allen JE; Lettau LA; Schwartz R; Appleby D
    Eur J Surg Suppl; 1992; (567):9-13. PubMed ID: 1381644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Open study of teicoplanin in gram-positive infections.
    Walsh B; Drabu YJ; Mehtar S; Blakemore PH
    Int J Clin Pharmacol Res; 1988; 8(2):99-100. PubMed ID: 2967801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy and safety of teicoplanin.
    Stille W; Sietzen W; Dieterich HA; Fell JJ
    J Antimicrob Chemother; 1988 Jan; 21 Suppl A():69-79. PubMed ID: 2965134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teicoplanin in the treatment of infection caused by gram-positive organisms.
    Williams AH; Grüneberg RN; Webster A; Ridgway GL
    J Hosp Infect; 1986 Mar; 7 Suppl A():101-3. PubMed ID: 2871091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of bone, joint, and vascular-access-associated gram-positive bacterial infections with teicoplanin.
    Greenberg RN
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2392-7. PubMed ID: 2150908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evaluation of efficacy, pharmacokinetics, and safety of teicoplanin for serious gram-positive infections.
    Bibler MR; Frame PT; Hagler DN; Bode RB; Staneck JL; Thamlikitkul V; Harris JE; Haregewoin A; Bullock WE
    Antimicrob Agents Chemother; 1987 Feb; 31(2):207-12. PubMed ID: 2952062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy of serious gram-positive infections with teicoplanin.
    Davies AJ; Stone JM; Synott M
    Drugs Exp Clin Res; 1989; 15(1):29-31. PubMed ID: 2526010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teicoplanin in the treatment of skin and soft tissue infections: results of a multicentre study.
    Lang E; Földes M; Marghescu S
    Infection; 1991; 19(3):190-4. PubMed ID: 1832418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy and safety of teicoplanin in the treatment of gram-positive infections.
    Kempf P; Pompetzki H; Oppermann A; Wittenberger R; Siebert J; Fell JJ; Dieterich HA
    Infection; 1989; 17(3):177-81. PubMed ID: 2525529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Teicoplanin and Gram-positive coccus infections. Results of a multicenter study on 66 cases].
    Dureux JB; Canton P; Chavanet P; Chippaux C; Dupeyron JP; Estavoyer JM; Giorgi C; Jaeger A; Jehl F; Kazmierzack A
    Pathol Biol (Paris); 1987 May; 35(5):511-5. PubMed ID: 2956564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of intraventricular teicoplanin for the treatment of neurosurgical shunt infections.
    Cruciani M; Navarra A; Di Perri G; Andreoni M; Danzi MC; Concia E; Bassetti D
    Clin Infect Dis; 1992 Aug; 15(2):285-9. PubMed ID: 1387805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of efficacy and safety of teicoplanin in gram-positive infections: a multicentre study.
    Lang E; Schäfer V; Schaaf B; Dennhardt R
    Scand J Infect Dis Suppl; 1990; 72():54-60. PubMed ID: 2151067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The use of teicoplanin in neutropenic patients: values and limits].
    Espinouse D; Chomarat M
    Pathol Biol (Paris); 1990 Jun; 38(5 ( Pt 2)):552-6. PubMed ID: 2143573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teicoplanin in the treatment of infections caused by coagulase-negative staphylococci.
    Harding I; Garaud JJ
    J Antimicrob Chemother; 1988 Jan; 21 Suppl A():93-103. PubMed ID: 2965137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.